Kent Imaging resolves ITC dispute with MolecuLight

Kent Imaging said it has reached an agreement with MolecuLight that ends their U.S. International Trade Commission case. The company said SnapshotGLO remains on the market and in clinical use as it continues to support wound care customers.

Why it matters: - The agreement removes an ongoing legal dispute that had been weighing on Kent Imaging’s business. - SnapshotGLO remains commercially available, which preserves access for clinicians using the device in wound care. - Kent Imaging said it continues to support healthcare professionals who rely on the technology.

What happened: - Kent Imaging announced on October 1, 2026, that it reached an agreement with MolecuLight to close the parties’ U.S. International Trade Commission case. - CEO Pierre Lemire said the company is refocusing on developing imaging technologies that provide clinicians with information to support patient care.

The details: - SnapshotGLO uses fluorescence imaging to help clinicians identify areas of elevated bacterial burden at the point of care. - The device supports wound assessment and clinical decision-making. - Kent Imaging said SnapshotGLO remains in active clinical use. - Kent Imaging said it is the only company with FDA-cleared devices for both fluorescence imaging through SnapshotGLO and tissue oxygenation measurement through SnapshotNIR. - The Snapshot product suite includes SnapshotNIR, a near-infrared tissue oxygenation imaging device. - SnapshotNIR was initially cleared by the FDA and Health Canada in 2017 and received CE marking in 2025. - SnapshotGLO received FDA 510(k) clearance in 2025.

Between the lines: - The resolution suggests Kent Imaging wants to shift attention from litigation to commercialization and clinical adoption. - The company is positioning its two-device portfolio as a broader platform for wound care, vascular care and surgical specialties. - Kent Imaging is using its regulatory footprint as a competitive differentiator in a crowded medical imaging market.

What's next: - Kent Imaging said it will keep supporting customers and clinical partners while advancing technologies aimed at better patient outcomes. - The company’s next focus appears to be expansion of use for the Snapshot product family rather than further dispute-related developments.

The bottom line: - Kent Imaging has cleared a legal hurdle and is moving back to execution on its wound care imaging business.